Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 5
2023 2
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean siragusa t[au] (2 results)?
Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity.
Vander Mause ER, Baker JM, Dietze KA, Radhakrishnan SV, Iraguha T, Omili D, Davis P, Chidester SL, Modzelewska K, Panse J, Marvin JE, Olson ML, Steinbach M, Ng DP, Lim CS, Atanackovic D, Luetkens T. Vander Mause ER, et al. Among authors: iraguha t. Sci Transl Med. 2023 Jul 19;15(705):eadd7900. doi: 10.1126/scitranslmed.add7900. Epub 2023 Jul 19. Sci Transl Med. 2023. PMID: 37467316
Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD).
Kline K, Chen W, Kallen ME, Koka R, Omili D, Fan X, Iraguha T, Gebru E, Dishanthan N, Baker JM, Dietze KA, Yared JA, Hankey K, Dahiya S, Niederhaus SV, Dunleavy K, Hardy NM, Luetkens T, Rapoport AP, Atanackovic D. Kline K, et al. Among authors: iraguha t. Hum Vaccin Immunother. 2023 Aug 1;19(2):2216116. doi: 10.1080/21645515.2023.2216116. Epub 2023 Jun 6. Hum Vaccin Immunother. 2023. PMID: 37278257 Free PMC article.
Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.
Kline K, Luetkens T, Koka R, Kallen ME, Chen W, Ahmad H, Omili D, Iraguha T, Gebru E, Fan X, Miller A, Dishanthan N, Baker JM, Dietze KA, Hankey KG, Yared JA, Hardy NM, Rapoport AP, Dahiya S, Atanackovic D. Kline K, et al. Among authors: iraguha t. Cancer Immunol Immunother. 2024 Feb 13;73(3):45. doi: 10.1007/s00262-023-03619-9. Cancer Immunol Immunother. 2024. PMID: 38349430 Free PMC article.
Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy.
Atanackovic D, Luetkens T, Omili D, Iraguha T, Lutfi F, Hardy NM, Fan X, Avila SV, Saharia KK, Husson JS, Niederhaus SV, Margiotta P, Lee ST, Law JY, Mannuel HD, Vander Mause E, Bauman S, Lesho P, Hankey K, Baddley J, Kocoglu M, Yared JA, Rapoport AP, Dahiya S. Atanackovic D, et al. Among authors: iraguha t. Blood. 2022 Jul 14;140(2):152-156. doi: 10.1182/blood.2022016175. Blood. 2022. PMID: 35537186 Free PMC article.
Restricting CAR T Cell Trafficking Expands Targetable Antigen Space.
Morales EA, Dietze KA, Baker JM, Wang A, Avila SV, Iglesias F, Radhakrishnan SV, Mause EV, Olson ML, Sun W, Rosati E, Chidester SL, Iraguha T, Fan X, Atanackovic D, Luetkens T. Morales EA, et al. Among authors: iraguha t. bioRxiv [Preprint]. 2024 Feb 11:2024.02.08.579002. doi: 10.1101/2024.02.08.579002. bioRxiv. 2024. PMID: 38370665 Free PMC article. Preprint.
Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy.
Dahiya S, Luetkens T, Lutfi F, Avila S, Iraguha T, Margiotta P, Hankey KG, Lesho P, Law JY, Lee ST, Baddley J, Kocoglu M, Yared JA, Hardy NM, Rapoport AP, Atanackovic D. Dahiya S, et al. Among authors: iraguha t. Blood Adv. 2022 Jan 25;6(2):686-689. doi: 10.1182/bloodadvances.2021006112. Blood Adv. 2022. PMID: 34941995 Free PMC article. No abstract available.
T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine.
Atanackovic D, Kreitman RJ, Cohen J, Hardy NM, Omili D, Iraguha T, Burbelo PD, Gebru E, Fan X, Baddley J, Luetkens T, Dahiya S, Rapoport AP. Atanackovic D, et al. Among authors: iraguha t. J Immunother Cancer. 2022 Jul;10(7):e004953. doi: 10.1136/jitc-2022-004953. J Immunother Cancer. 2022. PMID: 35851312 Free PMC article.
A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell products.
Atanackovic D, Iraguha T, Omili D, Avila SV, Fan X, Kocoglu M, Gebru E, Baker JM, Dishanthan N, Dietze KA, Oluwafemi A, Hardy NM, Yared JA, Hankey K, Dahiya S, Rapoport AP, Luetkens T. Atanackovic D, et al. Among authors: iraguha t. Cytotherapy. 2024 Apr;26(4):318-324. doi: 10.1016/j.jcyt.2024.01.006. Epub 2024 Feb 10. Cytotherapy. 2024. PMID: 38340107
Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells.
Kathari YK, Ahmad H, Kallen ME, Koka R, Omili D, Iraguha T, Clement J, Pham L, Khalid M, Fan X, Gebru E, Lesho P, Park E, Dishanthan N, Baker JM, Dietze KA, Hankey KG, Badros A, Yared JA, Dahiya S, Hardy NM, Kocoglu H, Luetkens T, Rapoport AP, Atanackovic D. Kathari YK, et al. Among authors: iraguha t. Haematologica. 2024 Feb 1;109(2):682-688. doi: 10.3324/haematol.2023.283296. Haematologica. 2024. PMID: 37675514 Free PMC article. No abstract available.
11 results